Promethera names chair of board
This article was originally published in Scrip
Promethera Biosciences, a Belgian biotechnology company developing a cell-based therapy for the treatment of in-born errors of metabolism and acquired liver diseases, has named Dr John Tchelingerian chair of its board of directors. Dr Tchelingerian is a serial entrepreneur and a private investor. He has co-founded and managed several biotech companies including Neurotech, Key-Obs and Diatos.